Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial

Fig. 3

Baseline IFNα protein levels do not predict remission after treatment. Baseline IFNα protein levels in plasma from patients with early RA, stratified according to CDAI 24 weeks after treatment initiation; in remission (CDAI 0–2.8), low disease activity (CDAI 2.9–10.0), and moderate/high disease activity (CDAI 10.1–76.0) with A all treatments, B methotrexate + prednisone, C methotrexate + TNFi, D methotrexate + CTLA-4Ig, and E methotrexate + IL-6Ri. MTX (methotrexate), TNFi (certolizumab-pegol), CTLA-4Ig (abatacept), IL-6Ri (tocilizumab). Kruskal-Wallis test followed by Dunn’s multiple comparison test

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us